by marketing@seuss.plus | Mar 23, 2023 | Uncategorized
– ANV600 is a potent, cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells – Basel, March 23, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600...
by admin | Mar 16, 2023 | Press Releases
– OMNIA-2 is a Phase I/II study evaluating ANV419 as monotherapy and in combination with daratumumab, or lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma – Basel, March 16, 2023 – Anaveon, a clinical stage,...